Vitamin D3 and K2 with GLP-1 Injections: Safety Assessment
Yes, it is safe to take vitamin D3 and K2 supplements while receiving GLP-1 receptor agonist injections—there are no known drug interactions or contraindications between these supplements and GLP-1 medications, and supplementation may actually be beneficial given emerging evidence of micronutrient deficiencies associated with GLP-1 therapy.
No Documented Contraindications
The FDA prescribing information for liraglutide (VICTOZA) does not list vitamin D3 or K2 as contraindicated substances or problematic drug interactions 1. The documented contraindications are limited to:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Serious hypersensitivity to liraglutide or excipients
No warnings exist regarding vitamin or mineral supplementation with GLP-1 receptor agonists.
Emerging Evidence Supports Supplementation
Recent research actually suggests that vitamin D supplementation may be particularly important for patients on GLP-1 therapy. A 2026 narrative review found that vitamin D deficiency was the most common micronutrient abnormality in GLP-1 users, occurring in 7.5% at 6 months and 13.6% at 12 months 2. The same study revealed that:
- More than 60% of GLP-1 users consumed below estimated requirements for calcium and iron
- Vitamin D intake averaged only 20% of recommendations
- Iron depletion was frequent, with 26-30% lower ferritin levels compared to other diabetes medications
- Calcium insufficiency contributed to lean mass loss
Mechanism and Rationale
GLP-1 receptor agonists predispose users to micronutrient deficiencies through three primary mechanisms 2:
- Appetite suppression leading to reduced overall food intake
- Delayed gastric emptying affecting nutrient absorption timing
- Altered absorption patterns in the gastrointestinal tract
Vitamin K2 works synergistically with vitamin D3 to optimize calcium metabolism and bone health—particularly relevant given the calcium insufficiency and lean mass loss observed in GLP-1 users 2.
Clinical Recommendation
Proceed with vitamin D3 and K2 supplementation without hesitation. In fact, consider:
- Baseline assessment: Check 25-hydroxyvitamin D levels before or early in GLP-1 therapy
- Standard dosing: Vitamin D3 1000-2000 IU daily with K2 (MK-7) 100-200 mcg daily
- Monitoring: Recheck vitamin D levels at 6-12 months, especially in patients with risk factors for deficiency
- Enhanced surveillance: For patients with additional malnutrition risk factors (restrictive eating, prior bariatric surgery, malabsorption disorders)
Important Caveats
While vitamin supplementation is safe, be aware of the documented adverse effects of GLP-1 therapy itself 1:
- Gastrointestinal effects (nausea, vomiting, diarrhea) occur in >5% of patients
- These may transiently affect supplement tolerance but do not contraindicate use
- Take supplements with food if GI symptoms occur
- The most serious GLP-1 risks (pancreatitis, acute kidney injury, gallbladder disease) are unrelated to vitamin supplementation
The combination is not only safe but potentially protective against the nutritional deficiencies that commonly develop during GLP-1 therapy.